Incident autoimmune diseases in association with SARS-CoV-2 infection : a matched cohort study
© 2023. International League of Associations for Rheumatology (ILAR)..
OBJECTIVES: To investigate whether the risk of developing an incident autoimmune disease is increased in patients with prior COVID-19 disease compared to those without COVID-19, a large cohort study was conducted.
METHOD: A cohort was selected from German routine health care data. Based on documented diagnoses, we identified individuals with polymerase chain reaction (PCR)-confirmed COVID-19 through December 31, 2020. Patients were matched 1:3 to control patients without COVID-19. Both groups were followed up until June 30, 2021. We used the four quarters preceding the index date until the end of follow-up to analyze the onset of autoimmune diseases during the post-acute period. Incidence rates (IR) per 1000 person-years were calculated for each outcome and patient group. Poisson models were deployed to estimate the incidence rate ratios (IRRs) of developing an autoimmune disease conditional on a preceding diagnosis of COVID-19.
RESULTS: In total, 641,704 patients with COVID-19 were included. Comparing the incidence rates in the COVID-19 (IR=15.05, 95% CI: 14.69-15.42) and matched control groups (IR=10.55, 95% CI: 10.25-10.86), we found a 42.63% higher likelihood of acquiring autoimmunity for patients who had suffered from COVID-19. This estimate was similar for common autoimmune diseases, such as Hashimoto thyroiditis, rheumatoid arthritis, or Sjögren syndrome. The highest IRR was observed for autoimmune diseases of the vasculitis group. Patients with a more severe course of COVID-19 were at a greater risk for incident autoimmune disease.
CONCLUSIONS: SARS-CoV-2 infection is associated with an increased risk of developing new-onset autoimmune diseases after the acute phase of infection. Key Points • In the 3 to 15 months after acute infection, patients who had suffered from COVID-19 had a 43% (95% CI: 37-48%) higher likelihood of developing a first-onset autoimmune disease, meaning an absolute increase in incidence of 4.50 per 1000 person-years over the control group. • COVID-19 showed the strongest association with vascular autoimmune diseases.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 42(2023), 10 vom: 19. Okt., Seite 2905-2914 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tesch, Falko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoimmune diseases |
|---|
| Anmerkungen: |
Date Completed 13.09.2023 Date Revised 16.11.2023 published: Print-Electronic ErratumIn: Clin Rheumatol. 2023 Jul 5;:. - PMID 37405528 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10067-023-06670-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358369517 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358369517 | ||
| 003 | DE-627 | ||
| 005 | 20231226074608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-023-06670-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358369517 | ||
| 035 | |a (NLM)37335408 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tesch, Falko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incident autoimmune diseases in association with SARS-CoV-2 infection |b a matched cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.09.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Clin Rheumatol. 2023 Jul 5;:. - PMID 37405528 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. International League of Associations for Rheumatology (ILAR). | ||
| 520 | |a OBJECTIVES: To investigate whether the risk of developing an incident autoimmune disease is increased in patients with prior COVID-19 disease compared to those without COVID-19, a large cohort study was conducted | ||
| 520 | |a METHOD: A cohort was selected from German routine health care data. Based on documented diagnoses, we identified individuals with polymerase chain reaction (PCR)-confirmed COVID-19 through December 31, 2020. Patients were matched 1:3 to control patients without COVID-19. Both groups were followed up until June 30, 2021. We used the four quarters preceding the index date until the end of follow-up to analyze the onset of autoimmune diseases during the post-acute period. Incidence rates (IR) per 1000 person-years were calculated for each outcome and patient group. Poisson models were deployed to estimate the incidence rate ratios (IRRs) of developing an autoimmune disease conditional on a preceding diagnosis of COVID-19 | ||
| 520 | |a RESULTS: In total, 641,704 patients with COVID-19 were included. Comparing the incidence rates in the COVID-19 (IR=15.05, 95% CI: 14.69-15.42) and matched control groups (IR=10.55, 95% CI: 10.25-10.86), we found a 42.63% higher likelihood of acquiring autoimmunity for patients who had suffered from COVID-19. This estimate was similar for common autoimmune diseases, such as Hashimoto thyroiditis, rheumatoid arthritis, or Sjögren syndrome. The highest IRR was observed for autoimmune diseases of the vasculitis group. Patients with a more severe course of COVID-19 were at a greater risk for incident autoimmune disease | ||
| 520 | |a CONCLUSIONS: SARS-CoV-2 infection is associated with an increased risk of developing new-onset autoimmune diseases after the acute phase of infection. Key Points • In the 3 to 15 months after acute infection, patients who had suffered from COVID-19 had a 43% (95% CI: 37-48%) higher likelihood of developing a first-onset autoimmune disease, meaning an absolute increase in incidence of 4.50 per 1000 person-years over the control group. • COVID-19 showed the strongest association with vascular autoimmune diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autoimmune diseases | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Claims data | |
| 650 | 4 | |a Cohort study | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Ehm, Franz |e verfasserin |4 aut | |
| 700 | 1 | |a Vivirito, Annika |e verfasserin |4 aut | |
| 700 | 1 | |a Wende, Danny |e verfasserin |4 aut | |
| 700 | 1 | |a Batram, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Loser, Friedrich |e verfasserin |4 aut | |
| 700 | 1 | |a Menzer, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Jacob, Josephine |e verfasserin |4 aut | |
| 700 | 1 | |a Roessler, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Seifert, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Kind, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a König, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Schulte, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Buschmann, Tilo |e verfasserin |4 aut | |
| 700 | 1 | |a Hertle, Dagmar |e verfasserin |4 aut | |
| 700 | 1 | |a Ballesteros, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Baßler, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Bertele, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Bitterer, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Riederer, Cordula |e verfasserin |4 aut | |
| 700 | 1 | |a Sobik, Franziska |e verfasserin |4 aut | |
| 700 | 1 | |a Reitzle, Lukas |e verfasserin |4 aut | |
| 700 | 1 | |a Scheidt-Nave, Christa |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitt, Jochen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d 1987 |g 42(2023), 10 vom: 19. Okt., Seite 2905-2914 |w (DE-627)NLM012613037 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:10 |g day:19 |g month:10 |g pages:2905-2914 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10067-023-06670-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 10 |b 19 |c 10 |h 2905-2914 | ||